AngioDynamics Named One of BusinessWeek's Top 100 Hot Growth Companies for 2005
AngioDynamics Named One of BusinessWeek's Top 100 Hot Growth Companies for 2005QUEENSBURY, N.Y.--(BUSINESS WIRE)--June 2, 2005--AngioDynamics, Inc. (NASDAQ:ANGO) today announced that it was named in the June 6, 2005 issue of BusinessWeek as one of the 100 best small public companies in the United States. The cover page article called "Hot Growth" is a part of an annual survey of top producing growth companies in a variety of sectors.
In selecting the top companies, BusinessWeek consults its database of 2,200 publicly traded companies with revenues of $50 million to $1.5 billion a year. The companies are then ranked by sales and earnings growth, as well as return on capital over three years. Contenders must have a market cap of $25 million or more and a stock price of at least $5 per share. The article may be accessed on BusinessWeek's web site at http://www.businessweek.com/magazine/content/05_23/b3936401.htm.
"It is always gratifying to be recognized by publications such as BusinessWeek that pay attention to the track record we have built over the past few years," commented Eamonn P. Hobbs, President and CEO of AngioDynamics. "We remain committed to growing our business by focusing on serving the current and future needs of the peripheral vascular disease market with innovative products."
AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of products used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the outcome of the Diomed patent litigation, the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Form 10-Q for the quarter ended February 26, 2005, and its Annual Report on Form 10-K for the year ended May 29, 2004, may affect the actual results achieved by the Company.
CONTACT: AngioDynamics, Inc. Joe Gerardi, 800-772-6446, ext. 115 www.angiodynamics.com or Investor Relations Contacts: Lippert/Heilshorn & Associates, Inc. Kim Sutton Golodetz (email@example.com) 212-838-3777 Bruce Voss (firstname.lastname@example.org) 310-691-7100 SOURCE: AngioDynamics, Inc.